CIK 0001678660
- Non-accelerated filer
- Smaller reporting company
Prelude Therapeutics Inc
Sign in to watch- Ticker
- PRLD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811384762
- Phone
- +1 302-467-1280
- Business address
- 175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805
- Former names
- Prelude Therapeutics Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-10-05 | Mauro David J Chief Medical Officer | Sale | −7,803 | $31.30 | $244K | 1,289 |
| 2021-10-05 | Mauro David J Chief Medical Officer | Sale | −1,289 | $32.06 | $41K | 0 |
| 2021-10-05 | Mauro David J Chief Medical Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −15,000 | 137,610 | ||
| 2021-09-07 | Mauro David J Chief Medical Officer | Exercise or conversion | +15,000 | $1.89 | $28K | 15,000 |
| 2021-09-07 | Mauro David J Chief Medical Officer | Sale | −7,487 | $35.91 | $269K | 7,513 |
| 2021-09-07 | Mauro David J Chief Medical Officer | Sale | −2,873 | $36.92 | $106K | 4,640 |
| 2021-09-07 | Mauro David J Chief Medical Officer | Sale | −4,640 | $37.79 | $175K | 0 |
| 2021-09-07 | Mauro David J Chief Medical Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −15,000 | 167,610 | ||
| 2021-09-02 | Pierce Christopher EVP and Chief of Business Oper | Exercise or conversion | +17,000 | $12.85 | $218K | 20,750 |
| 2021-09-02 | Pierce Christopher EVP and Chief of Business Oper | Sale | −3,343 | $40.29 | $135K | 17,407 |
| 2021-09-02 | Pierce Christopher EVP and Chief of Business Oper | Sale | −6,727 | $41.52 | $279K | 10,680 |
| 2021-09-02 | Pierce Christopher EVP and Chief of Business Oper | Sale | −6,930 | $42.50 | $295K | 3,750 |
| 2021-09-02 | Pierce Christopher EVP and Chief of Business Oper | Exercise or conversion · Employee Stock Option (right to buy) | −17,000 | 207,796 | ||
| 2021-08-27 | Scherle Peggy Chief Scientific Officer | Exercise or conversion | +6,014 | $1.43 | $9K | 178,934 |
| 2021-08-27 | Scherle Peggy Chief Scientific Officer | Sale | −2,700 | $35.32 | $95K | 176,234 |
| 2021-08-27 | Scherle Peggy Chief Scientific Officer | Sale | −2,707 | $36.23 | $98K | 173,527 |
| 2021-08-27 | Scherle Peggy Chief Scientific Officer | Sale | −607 | $37.08 | $23K | 172,920 |
| 2021-08-27 | Scherle Peggy Chief Scientific Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −6,014 | 27,018 | ||
| 2021-08-26 | Scherle Peggy Chief Scientific Officer | Exercise or conversion | +1,700 | $1.43 | $2K | 174,620 |
| 2021-08-26 | Scherle Peggy Chief Scientific Officer | Sale | −1,700 | $35.19 | $60K | 172,920 |
Page 9 of 19 · 369 trades